We will provide a comprehensive review of our current drug development pipeline, including the latest information on:
TDI 846 (Biogen Idec and UCB Pharma effort)
TDI 132 (clinical trial on Gilenya in ALS patients)
TDP43 mouse model charectorization
Steve Perrin, Ph.D.
John Lincecum, Ph.D.
Fernando G. Vieira, M.D.